The role of C-reactive protein in type 2 diabetes and its macrovascular complications in Chinese

Diabetes Research and Clinical Practice

Volumn 61, Issue 2, 2003, Pages 143-144

  Wu, Weihua ^a,b   Liu, Guoliang ^a   Yu, Jiangbo ^b   Zhang, Jinchao ^c   Wang, Xi ^c,d   Kasai, Kikuo ^d  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INSULIN; THIAZOLIDINE DERIVATIVE;

ARTERIOSCLEROSIS; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LETTER; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RISK FACTOR; VASCULAR DISEASE;

EID: 0042388510     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00083-4     Document Type: Letter

References (5)

1. Maseri A. Inflammation, arteriosclerosis, and ischemic events-exploring the hidden side of the moon. New Engl. J. Med. 336:1997;1014-1016.
2. Stern M.P. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes. 44:1995;369-374.
3. Haidari M., Javadi E., Sadeghi B., Hajilooi-Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin. Biochem. 33:2001;309-315.
4. Verma S., Li S.H., Badiwada M.V., Weisel R.D., Fedak P.W., Li R.K., Dhillon B., Fickle D.A. Endothelia antagonism and interleukin-6 inhibition attenuate the proathelogenic effects of C-reactive protein. Circulation. 105:2002;1890-1896.
5. Dandona P., Aliada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am. J. Cardiol. 90:2002;27G-33G.